Sort by
Items per page

Send to

Choose Destination

Search results

Items: 6


Development of a multicellular pancreatic tumor microenvironment system using patient-derived tumor cells.

Gioeli D, Snow CJ, Simmers MB, Hoang SA, Figler RA, Allende JA, Roller DG, Parsons JT, Wulfkuhle JD, Petricoin EF, Bauer TW, Wamhoff BR.

Lab Chip. 2019 Mar 27;19(7):1193-1204. doi: 10.1039/c8lc00755a.


Combinatorial drug screening and molecular profiling reveal diverse mechanisms of intrinsic and adaptive resistance to BRAF inhibition in V600E BRAF mutant melanomas.

Roller DG, Capaldo B, Bekiranov S, Mackey AJ, Conaway MR, Petricoin EF, Gioeli D, Weber MJ.

Oncotarget. 2016 Jan 19;7(3):2734-53. doi: 10.18632/oncotarget.6548.


Synthetic lethal screening with small-molecule inhibitors provides a pathway to rational combination therapies for melanoma.

Roller DG, Axelrod M, Capaldo BJ, Jensen K, Mackey A, Weber MJ, Gioeli D.

Mol Cancer Ther. 2012 Nov;11(11):2505-15. doi: 10.1158/1535-7163.MCT-12-0461. Epub 2012 Sep 7.


Role of the UL45 protein in herpes simplex virus entry via low pH-dependent endocytosis and its relationship to the conformation and function of glycoprotein B.

Dollery SJ, Lane KD, Delboy MG, Roller DG, Nicola AV.

Virus Res. 2010 Apr;149(1):115-8. doi: 10.1016/j.virusres.2010.01.004. Epub 2010 Jan 18.


Structure-function analysis of herpes simplex virus glycoprotein B with fusion-from-without activity.

Roller DG, Dollery SJ, Doyle JL, Nicola AV.

Virology. 2008 Dec 20;382(2):207-16. doi: 10.1016/j.virol.2008.09.015. Epub 2008 Oct 23.


Cellular proteasome activity facilitates herpes simplex virus entry at a postpenetration step.

Delboy MG, Roller DG, Nicola AV.

J Virol. 2008 Apr;82(7):3381-90. doi: 10.1128/JVI.02296-07. Epub 2008 Jan 30.

Supplemental Content

Loading ...
Support Center